The Dangerous Drugs Board (DDB) is saddened by recent news of lives lost due to alleged drug taking.
As the country’s lead agency on drug prevention and control, the DDB will conscientiously monitor the investigation of this case, make responsible parties answer for any lapses in security and violation of laws, and review existing policies and programs to prevent incidents such as this from happening.
We would also like to remind the public especially the youth to be vigilant and wary especially now that our law enforcement agencies have recorded a rise in the incidence of abuse of new psychoactive substances.
Like what we always say in our campaigns, what these drugs and substances offer is a false panacea. They offer nothing than a false and fleeting high with dangers that can sometimes lead to death.
As we strengthen law enforcement efforts and intelligence operations to arrest drug syndicates and perpetrators, we will also intensify our drug prevention and awareness programs to educate the people on the ill effects of drugs and capacitate and empower them to resist its lures.
To integrate and coordinate efforts of the criminal justice system in the prosecution and criminal investigation of drug-related cases, the Dangerous Drugs Board (DDB) in collaboration with the Philippine Judicial Academy (PhilJa) convened judges, prosecutors and law enforcers from Region IV in a seminar-workshop on RA 9165 or the Comprehensive Dangerous Drugs Act of 2002.
Held on May 17-20 at Taal Vista Hotel, Tagaytay City, the seminar-workshop aimed to update the participants on the list of dangerous drugs and controlled chemicals and to apprise them of RA 9165 provisions and other DDB regulations.
The event likewise served as a forum to identify problems encountered in prosecuting drug-related cases, enhance knowledge on handling drug evidence, and share well-tested trial techniques backed by new procedures and latest jurisprudence.
DDB Chairman Sec. Felipe L. Rojas, Jr., led the opening ceremonies and expressed his joy over the support and participation of the criminal justice pillars.
The seminar, according to Sec. Rojas, shows the intensified effort of the government against illegal drugs. “Our assembly today signifies that we are not letting down on our fight against drugs, nor are we cutting lose our reign on programs that counter this menace,” Sec. Rojas said.
Parole and Probation Officers (PPOs) from NCR, Regions II to V and CAR are now authorized to process petitions for confinement to treatment and rehabilitation centers.
In an orientation seminar conducted by the Dangerous Drugs Board last week, 96 PPOs were enlisted as DDB-authorized representatives who can now facilitate requests or petitions from drug dependents or their families who wish to be admitted to a treatment and rehabilitation facility.
New DDB-authorized representatives are from the National Capital Region (NCR), Regions II, III, IV, V and Cordillera Administrative Region.
This will answer concerns on the absence of legal officers in the regions to help facilitate petition for confinement to treatment and rehabilitation.
The DDB has a standing Memorandum of Agreement (MOA) with the Parole and Probation Administration (PPA) that authorizes PPOs to be designated as DDB representatives to assist patients from different regions in filing court petitions for treatment and rehabilitation.
During the orientation seminar, Usec. Jose Marlowe S. Pedregosa, DDB Executive Director, emphasized the big role of PPOs in helping provide accessible services to the public especially those in the regions.
Selected PPOs who are now DDB-authorized representatives are oriented on their duties and responsibilities in facilitating and processing petitions for confinement, the treatment and rehabilitation process, as well as the aftercare program.
All countries around the world unite again to discuss issues about the world drug problem in the United Nations General Assembly Special Session on Drugs in New York City, USA from 19-21 April 2016.
Dangerous Drugs Board (DDB) Chairman Sec. Felipe L. Rojas Jr., together with Permanent Board Member Usec. Edgar C. Galvante, and other officials from the Board’s member agencies such as the Department of Justice (DOJ), Department of Health (DOH), and the Philippine Drug Enforcement Agency (PDEA) form part of the Philippine delegation to the forum where they will also report on the country’s drug prevention and control accomplishments and plans to address new issues and challenges on the anti-drug fight.
Among the most pressing concerns that the assembly will discuss are the development and implementation of strategies anchored on human rights-based approaches and identification of effective responses to social and health impacts of drugs.
In line with this, the Philippine delegation will report on the institutionalization of the country’s National Anti-Drug Plan of Action or NADPA, a comprehensive plan that balances supply and demand reduction efforts, strengthening preventive education programs as well as treatment and rehabilitation services. It also promotes alternative development, elicits social response and facilitates regional and international cooperation.
UN convenes a special session on the world drug problem to review progress in the implementation of the Political Declaration and Plan of Action on International Cooperation towards an integrated and balanced strategy to counter the world drug problem. It is also a way of assessing the achievements and challenges in countering the world drug problem, within the framework of the three (3) international drug control conventions and other relevant United Nations instruments.
Responding to requests of legitimate industries led by Samahan sa Pilipinas ng Industriyang Kemika, the Dangerous Drugs Board has decided to extend the moratorium on the ban of spray paints and glue with toluene concentrations equal to or higher than 0.1% by weight.
A regulation issued by the DDB in 2014 which took effect on March 13, 2015 banned the sale of toluene-based spray paints and glue to the general public. This move was made to address the increasing incidents of abuse of toluene-based inhalants.
However, recognizing the legitimate use of toluene by manufacturers and other industries, the DDB has issued a moratorium on the implementation of this provision. Legitimate users are given a one-year moratorium which ended on March 12, 2016.
Since January, the DDB has been receiving requests for the extension of this moratorium and during its 168th meeting on April 13, 2016, the Board has approved a resolution extending the moratorium until September 30, 2016.
This was after a careful evaluation and recommendation of a Technical Working Group and consideration of the principle that regulations should not hamper the operations of legitimate industries.
During the meeting, Usec. Edgar C. Galvante, DDB Permanent Member, raised the motion to grant the extension. It was seconded by Usec. Alberto T. Muyot, ex-officio member representing the Secretary of the Department of Education. With the members of the Board having no objection, DDB Chairman Sec. Flipe L. Rojas, Jr., granted the motion.
Aside from extending this moratorium, the Board during its meeting has also approved the grant of subsistence allowance for patients in drug treatment and rehabilitation centers in Bataan, Caraga, Argao and Malinao.
As the policy-making and strategy-formulating body on drug prevention and control, the DDB has the power to issue regulations or resolutions that have the effect of a law. These are deliberated during meetings conducted regularly with members of the Board.
The 168th Board Meeting is the first meeting presided by Sec. Rojas, the newly appointed Chairman of the Board.
To all concerned clients and stakeholders:
The Legal Division of the Dangerous Drugs Board receives numerous requests for Certificate of No Controlled Chemicals and Certificate of Exemption. In a bid to efficiently process and proficiently evaluate all these requests, we will be implementing a schedule for the submission of applications and walk-in inquiries.
Starting on 20 July 2015 (Monday), submission of applicants and walk-in inquiries shall be accommodated by our personnel from 8:00 AM to 2:00 PM on regular office days. This will allow us to process applications thereafter.
We are hoping for your understanding and cooperation.
Dangerous Drugs Board
To all Physicians, Dentists, Veterinarians, or Practitioners:
The Department of Health-Special Concerns Technical Cluster-Dangerous Drug Abuse Prevention and Treatment Program (SCTC-DDAPTP) announces the availability of Yellow Prescription Pads for sale at selected DOH distribution sites. (Please see complete list under Downloads section in the side bar portion of the DDB website).
FOR: APPLICANTS FOR ISSUANCE OF CERTIFICATE OF NON-CONTROLLED CHEMICALS AND CERTIFICATE OF EXEMPTION
FROM: DDB LEGAL
Effective February 4, 2015 (Wednesday), all applications and attached annexes for certificate of non-controlled chemicals and certificate of exemtion shall submitted in pdf format of said application and attached annexes to be placed in a CD or USB Flash Drive. The requirement aims to improve file management and reduce paper usage in the office.
Applications submitted after the said date without the soft copy requirement shall not be accepted.
Thank you for your cooperation.
Please enclose a SELF - ADDRESSED STAMPED ENVELOPE if you wish to have your certification / exemption mailed to your company through registered mail only. Please ensure that you have placed the proper amount of stamps in a legal - size envelope in order to have the certification / exemption delivered through registerd mail.
TO: ALL PHYSICIANS, DENTISTS, VETERINARIANS AND PHARMACISTS
In the interest of public service, please be informed that due to unavailability of the DOH-Special Prescription Form (Yellow Pad), the use of Ordinary Personalized Prescription Form is HEREBY EXTENDED UNTIL SUCH TIME THE DOH SPECIAL PRESCRIPTION FORMS shall be readily available.
Furthermore, the same shall be in triplicate form, the ordinary copy of which shall be surrendered to the drugstore or pharmacy that dispense the dangerous drugs, the duplicate copy shall remain with the patient or purchaser-representative, and the third copy shall be retained by the prescribing physician.
This advisory shall take effect immediately.
(Sgd) Undersecretary JOSE MARLOWE S. PEDREGOSA
05 April 2013